VAUGHAN, Ontario—Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, has announced that Health Canada has approved the enVista Envy full visual range intraocular lens (IOL). This is the first global regulatory approval of the new lens, which offers a full range of vision with strong dysphotopsia tolerance on the enVista IOL platform, according to the company. “enVista Envy is the next step in the dramatic transformation of our IOL portfolio,” said Luc Bonnefoy, president, global surgical, Bausch + Lomb.

“This first premium IOL on the enVista platform follows the U.S. launch of enVista Aspire late last year. The company plans to launch complementary designs to round out the well-known enVista portfolio in the coming months to better address all patient needs.”

The enVista Envy features ActivSync Optic Intelligent Energy Distribution, optimizing vision in every lighting condition, and ClearPath technology, which helps reduce light scattering, the company said. Low-Cyl toric technology allows the enVista Envy toric lens to simultaneously treat presbyopia and low amounts of astigmatism while offering more precision with 0.5D steps (or less) throughout the cylinder range.

“Today’s cataract patients live vibrant, active lives and have high expectations for vision following surgery,” said Adam Muzychuk, MD, of the University of Calgary. “The attributes of enVista Envy, particularly its full range of vision, with very low rates of visual disturbances, position it as an exciting option for patients hoping to live life with greater freedom from glasses and contact lenses. I look forward to offering it in my practice.”

enVista Envy IOLs will be commercially available in Canada mid-June. Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets, including the U.S. and Europe, the company said. The enVista Envy IOL is pending FDA approval and is not approved for sale or distribution in the United States or its territories.